GlassScriptPhysician profile
Michael Coan Coan
NPI 1386955904
$10,302.10
in general payments reported to CMS, 2019-2025
29 companies · $2,355 in 2025
The $2,355 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,553 · 2020: $476 · 2021: $384 · 2022: $1,013 · 2023: $1,494 · 2024: $2,028 · 2025: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,876.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,571.89 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $2,408.41 | 2019-2025 | Rinvoq |
| Lilly USA, LLC | $1,015.02 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Astrazeneca Pharmaceuticals LP | $627.59 | 2023-2025 | Saphnelo |
| Ucb, INC. | $564.30 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $484.91 | 2019-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $473.56 | 2019-2025 | |
| Genentech USA, INC. | $419.00 | 2019-2020 | |
| Pfizer INC. | $417.93 | 2019-2025 | |
| Janssen Biotech, INC. | $272.72 | 2021-2025 | Tremfya |
| Horizon Therapeutics Plc | $271.80 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.70 | 2019-2024 | Ofev, Cyltezo |
| Genzyme Corporation | $110.16 | 2023-2025 | |
| Sobi, INC | $80.64 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $66.50 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $53.65 | 2024 | Arcalyst |
| Celgene Corporation | $52.99 | 2019 | |
| Ferring Pharmaceuticals INC. | $47.54 | 2019 | |
| Organon LLC | $47.30 | 2023-2025 | Renflexis, Hadlima |
| Kiniksa Pharmaceuticals, LTD. | $43.59 | 2023 | Arcalyst |
| Fidia Pharma USA INC. | $28.47 | 2025 | Triluron, Hymovis |
| Fresenius Kabi USA, LLC | $26.23 | 2023 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $23.81 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $20.43 | 2023 | Lupkynis |
| Zimmer Biomet Holdings, INC. | $17.16 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.50 | 2025 | Oxlumo |
| Actelion Pharmaceuticals US, INC. | $15.06 | 2025 | Opsumit |
| Medtronic, INC. | $14.24 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Coan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.